These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21810527)

  • 1. Official Positions for FRAX(®) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX(®) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®).
    Leib ES; Saag KG; Adachi JD; Geusens PP; Binkley N; McCloskey EV; Hans DB;
    J Clin Densitom; 2011; 14(3):212-9. PubMed ID: 21810527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Official Positions for FRAX® clinical regarding rheumatoid arthritis from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
    Broy SB; Tanner SB;
    J Clin Densitom; 2011; 14(3):184-9. PubMed ID: 21810523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Official Positions for FRAX® clinical regarding prior fractures from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
    Blank RD;
    J Clin Densitom; 2011; 14(3):205-11. PubMed ID: 21810526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Official Positions for FRAX® clinical regarding falls and frailty: can falls and frailty be used in FRAX®? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
    Masud T; Binkley N; Boonen S; Hannan MT;
    J Clin Densitom; 2011; 14(3):194-204. PubMed ID: 21810525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
    Lewiecki EM; Compston JE; Miller PD; Adachi JD; Adams JE; Leslie WD; Kanis JA; Moayyeri A; Adler RA; Hans DB; Kendler DL; Diez-Perez A; Krieg MA; Masri BK; Lorenc RR; Bauer DC; Blake GM; Josse RG; Clark P; Khan AA;
    J Clin Densitom; 2011; 14(3):226-36. PubMed ID: 21810530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FRAX® International Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.
    Cauley JA; El-Hajj Fuleihan G; Luckey MM;
    J Clin Densitom; 2011; 14(3):237-9. PubMed ID: 21810531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice.
    Hans DB; Kanis JA; Baim S; Bilezikian JP; Binkley N; Cauley JA; Compston JE; Cooper C; Dawson-Hughes B; El-Hajj Fuleihan G; Leslie WD; Lewiecki EM; Luckey MM; McCloskey EV; Papapoulos SE; Poiana C; Rizzoli R;
    J Clin Densitom; 2011; 14(3):171-80. PubMed ID: 21810521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FRAX(®) Clinical Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.
    McCloskey EV; Binkley N;
    J Clin Densitom; 2011; 14(3):181-3. PubMed ID: 21810522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Official Positions for FRAX® clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
    Cauley JA; El-Hajj Fuleihan G; Arabi A; Fujiwara S; Ragi-Eis S; Calderon A; Chionh SB; Chen Z; Curtis JR; Danielson ME; Hanley DA; Kroger H; Kung AW; Lesnyak O; Nieves J; Pluskiewicz W; El Rassi R; Silverman S; Schott AM; Rizzoli R; Luckey M;
    J Clin Densitom; 2011; 14(3):240-62. PubMed ID: 21810532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Official Positions for FRAX® clinical regarding smoking from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
    Dimai HP; Chandran M;
    J Clin Densitom; 2011; 14(3):190-3. PubMed ID: 21810524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidance for the adjustment of FRAX according to the dose of glucocorticoids.
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Osteoporos Int; 2011 Mar; 22(3):809-16. PubMed ID: 21229233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.
    Lewiecki EM; Compston JE; Miller PD; Adachi JD; Adams JE; Leslie WD; Kanis JA;
    J Clin Densitom; 2011; 14(3):223-5. PubMed ID: 21810529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
    McCloskey EV; Vasikaran S; Cooper C;
    J Clin Densitom; 2011; 14(3):220-2. PubMed ID: 21810528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus of official position of IOF/ISCD FRAX initiatives in Asia-Pacific region.
    Wu CH; McCloskey EV; Lee JK; Itabashi A; Prince R; Yu W; Li-Yu J; Chionh SB; Zhao Y; Shin CS; Gunawan T; Tsai KS; Chieng PU; Changlai SP; Chan DC; Chen JF; Tanner SB; Hans DB; Kanis JA; Chang YF; Sun ZJ; Yang RS;
    J Clin Densitom; 2014; 17(1):150-5. PubMed ID: 23916756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteoporosis - whom to treat? The importance of FRAX® in Switzerland].
    Lippuner K
    Ther Umsch; 2012 Mar; 69(3):207-13. PubMed ID: 22403115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
    Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
    Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An update on glucocorticoid-induced osteoporosis].
    Krasselt M; Baerwald C
    Dtsch Med Wochenschr; 2016 Mar; 141(5):352-7. PubMed ID: 26939107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey.
    Yu SF; Chen JF; Chen YC; Lai HM; Ko CH; Chiu WC; Su FM; Hsu CY; Su BY; Wu CH; Cheng TT
    Medicine (Baltimore); 2017 Feb; 96(5):e5959. PubMed ID: 28151883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between osteoporotic fracture risk in Brazilian postmenopausal women calculated using the FRAX with and without the inclusion of bone densitometry data.
    Bastos-Silva Y; Aguiar LB; Pinto-Neto AM; Baccaro LF; Costa-Paiva L
    Arch Osteoporos; 2016; 11():16. PubMed ID: 27067597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis.
    Pereira RM; Carvalho JF; Paula AP; Zerbini C; Domiciano DS; Gonçalves H; Danowski JS; Marques Neto JF; Mendonça LM; Bezerra MC; Terreri MT; Imamura M; Weingrill P; Plapler PG; Radominski S; Tourinho T; Szejnfeld VL; Andrada NC; ; ;
    Rev Bras Reumatol; 2012 Aug; 52(4):580-93. PubMed ID: 22885424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.